The mechanism of action of intravenous immunoglobulin (IVIg) and polyclonal anti-Dmediated reversal of immune thrombocytopenia is still unclear. However, in a murine model of ITP, the therapeutic effect of IVIg appears to be wholly dependent upon the expression of the inhibitory Fc receptor, Fc RIIB. We previously demonstrated that, similar to anti-D in humans, two erythrocytereactive monoclonal antibodies (TER119 and M1/69) ameliorated murine ITP and inhibited RES function at doses which protected against thrombocytopenia. The current study evaluated the involvement of the inhibitory and activating Fc receptors, Fc RIIB and Fc RIIIA, respectively, in the TER119 and M1/69-mediated inhibition of thrombocytopenia. In contrast to IVIg, in Fc RIIB deficient mice both monoclonal antibodies ameliorated ITP and both significantly down-regulated the level of expression of the activating Fc RIIIA in splenic macrophages. 
Song-3 INTRODUCTION
Intravenous immunoglobulin (IVIg) is widely used in the treatment of various autoimmune conditions, including immune thrombocytopenic purpura (ITP). Many mechanisms have been suggested to explain the therapeutic effectiveness of IVIg in increasing platelet counts in ITP. The predominant hypotheses are Fc receptor (Fc R) blockade, anti-idiotypic regulation and immunomodulation. [1] [2] [3] [4] [5] It has also been suggested that the MHC class I-like Fc receptor (FcRn) may play a role in the action of IVIg. 6 Recently, the ratio of activating Fc RIII and the inhibitory Fc RIIB expression on splenic macrophages has been proposed to be a key to the therapeutic effectiveness of IVIg, as IVIg up-regulates Fc RIIB expression in wild-type mice (Fc RIIB +/+ ) and the absence of Fc RIIB (Fc RIIB -/-) completely abrogates the therapeutic efficacy of IVIg in thrombocytopenic mice. 7 IVIg and anti-D may utilize different pathways to produce their therapeutic effects. [7] [8] [9] [10] [11] [12] [13] [14] [15] We have previously demonstrated that two monoclonal anti-erythrocyte antibodies, TER119 and M1/69, mimic the effect of anti-D in reversing thrombocytopenia in a murine model of ITP; amelioration of thrombocytopenia correlated with an impaired ability to clear sensitized erythrocytes. 16 The current study shows that, unlike IVIg, these therapeutic anti-erythrocyte monoclonal antibodies reverse thrombocytopenia in a Fc RIIB-independent fashion, possibly by blocking or decreasing the level of functional Fc RIIIA expression. This suggests that, in contrast to IVIg, anti-D-like monoclonal antibodies ameliorate ITP via inhibition of activating Fc receptors.
Materials and Methods

Mice
Fc RIIB -/-mice (B6;129S4-Fcgr2b tm1Rav /J) and C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME. US) and housed at the St. Michael's Hospital Research Vivarium. Isoton II diluent (Coulter Corporation, Miami, FL, US) and platelet count determined using a Beckman Z2 Coulter Counter (Coulter Corporation).
Song-4 Induction and reversal of ITP
Induction and prevention of erythrocyte clearance
To block erythrocyte clearance, mice were injected intravenously with 50µg 2.4G2 (an Fc RIIB/Fc RIIIA blocking antibody) 19, 20 or rat IgG as negative control, or intraperitoneally with 2g/kg IVIg. After 2 hours, erythrocyte clearance was induced with the intravenous administration of 50µg TER119. After a further 24 hours, the blood was collected and erythrocytes enumerated as previously reported.
16
Preparation of splenocytes and flow cytometric analysis
Twenty four hours after treatment with TER119, M1/69, or 30-F1 (PharMingen) or IVIg as indicated above, the spleen was removed, mechanically disrupted in 5ml of PBS containing 0.5% BSA and filtered through 70µm nylon mesh strainer. 21 Erythrocytes were lysed using ACK lysis buffer 22 We have shown that the monoclonal erythrocyte-reactive antibodies TER119 and M1/69 successfully ameliorate murine ITP. 16 In the current study we tested these antibodies, as well as IVIg, for efficacy in treating thrombocytopenic Fc RIIB +/+ and Fc RIIB -/-mice. In agreement with previous publications, 7, 18 IVIg successfully reversed the disease in wild-type mice ( Fig 1A, ) but not in
Fc RIIB -/-mice (Fig 1B, ) . In contrast, TER119, and M1/69 demonstrated a successful therapeutic effect in both thrombocytopenic Fc RIIB +/+ (Fig 1A, , ) and Fc RIIB -/-mice (Fig 1B, , ) ,
indicating that TER119 and M1/69 can function fully independent of Fc RIIB expression. Since the antiplatelet antibody used in this study is completely dependent on Fc RIIIA expression for its pathologic effect (AR Crow, unpublished observations), we hypothesized that, since TER119 and M1/69 do not rely on Fc RIIB expression, they might function by blocking or down-modulating Fc RIIIA expression, leading to increased platelet survival.
Fc R-bearing splenic macrophages are the main cells mediating platelet destruction in ITP. 24 We have reported a positive correlation between the increase in platelet count and the clearance of erythrocytes by therapeutic anti-erythrocyte antibody in thrombocytopenic mice. 16 Hence we presumed that, unlike IVIg, anti-erythrocyte antibodies may functionally block and/or down-regulate the expression of Fc RIIIA, resulting in the decreased platelet phagocytosis. To define the possible modulating effect of these anti-erythrocyte antibodies on Fc RIIIA expression, we analyzed the expression of Fc RIIIA on splenic macrophages in Fc RIIB -/-mice after injection of the ITP-Song-6 ameliorating antibodies (TER119, M1/69), as well as after injection of an erythrocyte-reactive antibody (30-F1) that does not ameliorate ITP. 16 The administration of TER119 and M1/69, but not IVIg or 30-F1, significantly decreased the level of expression of Fc RIIIA (Fig 2A) In this report, we have used several monoclonal anti-erythrocyte specific antibodies to mimic the therapeutic effects of anti-D in ITP. The TER119 antigen is a molecule associated with cellsurface glycophorin A and the monoclonal antibody TER119 specifically recognizes murine erythrocytes. 26 Our previous study has demonstrated that TER119 mimics the action of anti-D to effectively ameliorate murine thrombocytopenia.
Song-7 monoclonal anti-D in 7 D-positive patients with chronic ITP was unsucessful 27 , this is in general agreement with our previous work which has demonstrated that not all monoclonal antierythrocyte antibodies can ameliorate murine ITP. 16 The monoclonal antibodies which effectively ameliorated the thrombocytopenia did react with the murine red cells and bound more strongly than did IVIg (supplemental Fig. S2 ). In contrast, the antibody less reactive (equivalent to the batch of 
